Clinical Trial

Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer

Study acronym: ultraHART
Recruiting
View on ClinicalTrials.gov →
Summary
In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-06; most recent amendment 2026-06-09.
Status change: Not Yet Recruiting → Recruiting 2026-06-09
Trial Details
NCT Number NCT06355050
Lead Sponsor Jena University Hospital
Collaborators: Klinikum Stuttgart, University Medical Center Göttingen, Kantonsspital Aarau, Hirslanden Stephanshorn, Radiologische Allianz Hamburg, University Hospital Freiburg
Conditions Prostate Cancer, Adaptive Radiotherapy, Quality of Life
Enrollment 150 participants
Start Date 2026-04-01
Primary Completion 2027-09-30 (estimated)
Study Completion 2032-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-11